- Home
- KNSA vs ATRC Comparison
KNSA vs ATRC Comparison
Compare KNSA & ATRC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNSA
- ATRC
- Stock Information
- Founded
- KNSA 2015
- ATRC 2000
- Country
- KNSA United Kingdom
- ATRC United States
- Employees
- KNSA N/A
- ATRC N/A
- Industry
- KNSA Biotechnology: Pharmaceutical Preparations
- ATRC Medical/Dental Instruments
- Sector
- KNSA Health Care
- ATRC Health Care
- Exchange
- KNSA Nasdaq
- ATRC Nasdaq
- Market Cap
- KNSA 1.5B
- ATRC 1.5B
- IPO Year
- KNSA 2018
- ATRC 2005
- Fundamental
- Price
- KNSA $20.21
- ATRC $32.01
- Analyst Decision
- KNSA Strong Buy
- ATRC Strong Buy
- Analyst Count
- KNSA 6
- ATRC 10
- Target Price
- KNSA $37.17
- ATRC $48.50
- AVG Volume (30 Days)
- KNSA 638.0K
- ATRC 556.9K
- Earning Date
- KNSA 04-29-2025
- ATRC 04-29-2025
- Dividend Yield
- KNSA N/A
- ATRC N/A
- EPS Growth
- KNSA N/A
- ATRC N/A
- EPS
- KNSA N/A
- ATRC N/A
- Revenue
- KNSA $423,239,000.00
- ATRC $465,307,000.00
- Revenue This Year
- KNSA $37.21
- ATRC $14.60
- Revenue Next Year
- KNSA $2.58
- ATRC $12.58
- P/E Ratio
- KNSA N/A
- ATRC N/A
- Revenue Growth
- KNSA 56.60
- ATRC 16.55
- 52 Week Low
- KNSA $16.56
- ATRC $18.94
- 52 Week High
- KNSA $28.15
- ATRC $43.11
- Technical
- Relative Strength Index (RSI)
- KNSA 44.56
- ATRC 43.87
- Support Level
- KNSA $18.26
- ATRC $29.48
- Resistance Level
- KNSA $21.24
- ATRC $33.56
- Average True Range (ATR)
- KNSA 1.12
- ATRC 2.13
- MACD
- KNSA -0.12
- ATRC 0.14
- Stochastic Oscillator
- KNSA 44.43
- ATRC 52.38
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
About ATRC AtriCure Inc.
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.